{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:09:20Z","timestamp":1789412960509,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.116981","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:49:25Z","timestamp":1781236165000},"page":"116981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of super V\u03b42 T cells for relapsed\/refractory acute myeloid Leukemia via non-viral site-specific integration"],"prefix":"10.1016","volume":"185","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-9180","authenticated-orcid":false,"given":"Leshuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4166-3226","authenticated-orcid":false,"given":"Yongzeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2026.116981_bb0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116981_bb0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic heterogeneity and clonal evolution in acute myeloid leukemia","volume":"28","author":"Romer-Seibert","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"7382","key":"10.1016\/j.intimp.2026.116981_bb0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.116981_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116981_bb0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.116981_bb0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.intimp.2026.116981_bb0040","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116981_bb0050","doi-asserted-by":"crossref","unstructured":"Budde, L., et al., Remissions of acute myeloid Leukemia and Blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood, 2017. 130: p. 811.","DOI":"10.1182\/blood.V130.Suppl_1.811.811"},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116981_bb0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u0393\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.116981_bb0065","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T cells show CAR-directed and independent activity against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116981_bb0070","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.26564","article-title":"Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study","volume":"97","author":"Tang","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2015.01.008","article-title":"Human V\u03b39\/V\u03b42 T cells: innate adaptors of the immune system","volume":"296","author":"Tyler","year":"2015","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116981_bb0085","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116981_bb0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.exphem.2008.04.010","article-title":"Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma","volume":"36","author":"Barber","year":"2008","journal-title":"Exp. Hematol."},{"issue":"22","key":"10.1016\/j.intimp.2026.116981_bb0095","doi-asserted-by":"crossref","first-page":"11029","DOI":"10.1158\/0008-5472.CAN-07-2251","article-title":"Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1074-7613(01)00168-6","article-title":"MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function","volume":"15","author":"Das","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116981_bb0105","doi-asserted-by":"crossref","unstructured":"Driouk, L., et al., Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid Leukemia and T-cell acute lymphoblastic Leukemia. Front. Immunol., 2020. 11: p. 580328.","DOI":"10.3389\/fimmu.2020.580328"},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: An in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116981_bb0115","first-page":"41","article-title":"The HL60 cell line: a model system for studying human myeloid cell differentiation","volume":"9","author":"Birnie","year":"1988","journal-title":"Br. J. Cancer Suppl."},{"issue":"7643","key":"10.1016\/j.intimp.2026.116981_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116981_bb0125","doi-asserted-by":"crossref","unstructured":"Sadelain, M. and J. Eyquem, Abstract IA22: targeting CARs to the TRAC locus enhances T-cell potency. Clin. Cancer Res., 2017. 23(24_Supplement): p. IA22-IA22.","DOI":"10.1158\/1557-3265.HEMMAL17-IA22"},{"issue":"4","key":"10.1016\/j.intimp.2026.116981_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/elsc.202200047","article-title":"Implementation of ubiquitous chromatin opening elements as artificial integration sites for CRISPR\/Cas9-mediated knock-in in mammalian cells","volume":"23","author":"Kim","year":"2023","journal-title":"Eng. Life Sci."},{"issue":"24","key":"10.1016\/j.intimp.2026.116981_bb0135","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1073\/pnas.85.24.9694","article-title":"Human T-cell antigen receptor (TCR) delta-chain locus and elements responsible for its deletion are within the TCR alpha-chain locus","volume":"85","author":"Hockett","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"7980","key":"10.1016\/j.intimp.2026.116981_bb0145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2026.116981_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/85321","article-title":"Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells","volume":"2","author":"Groh","year":"2001","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116981_bb0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ejh.13672","article-title":"Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients","volume":"107","author":"Ngai","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"7768","key":"10.1016\/j.intimp.2026.116981_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116981_bb0165","doi-asserted-by":"crossref","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.intimp.2026.116981_bb0170","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid Leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116981_bb0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cytogfr.2019.06.003","article-title":"CD14: biology and role in the pathogenesis of disease","volume":"48","author":"Wu","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2026.116981_bb0180","doi-asserted-by":"crossref","unstructured":"Korver, W., et al., CLL-1 is a potential target for the treatment of acute myeloid Leukemia. Blood, 2007. 110(11): p. 2839.","DOI":"10.1182\/blood.V110.11.2839.2839"},{"key":"10.1016\/j.intimp.2026.116981_bb0185","doi-asserted-by":"crossref","unstructured":"Rao, A., et al., Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J. Immunother. Cancer, 2024. 12(2).","DOI":"10.1136\/jitc-2023-007981"},{"key":"10.1016\/j.intimp.2026.116981_bb0190","doi-asserted-by":"crossref","unstructured":"Eckstrom, A., et al., Donor-derived Variable Delta 2 (V\u03b42) Gamma Delta (\u03b3\u03b4) T cells: a promising off-the-shelf therapeutic strategy for acute myeloid Leukemia. Blood, 2024. 144(Supplement 1): p. 7186\u20137186.","DOI":"10.1182\/blood-2024-211031"},{"key":"10.1016\/j.intimp.2026.116981_bb0195","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3389\/fimmu.2019.01342","article-title":"Graft engineering and adoptive immunotherapy: new approaches to promote immune tolerance after hematopoietic stem cell transplantation","volume":"10","author":"Bertaina","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116981_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116981_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1492","article-title":"Effective \u03b3\u03b4 T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy","volume":"13","author":"Revesz","year":"2024","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.intimp.2026.116981_bb0210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2014.00601","article-title":"Cancer immunotherapy using \u03b3\u03b4T cells: dealing with diversity","volume":"5","author":"Scheper","year":"2014","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116981_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451074","article-title":"The potential of \u03b3\u03b4 CAR and TRuC T cells: an unearthed treasure","volume":"54","author":"Schamel","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116981_bb0220","doi-asserted-by":"crossref","unstructured":"Trembath, A.P. and M.A. Markiewicz, More than decoration: roles for natural killer group 2 member D ligand expression by immune cells. Front. Immunol., 2018. 9: p. 231.","DOI":"10.3389\/fimmu.2018.00231"},{"issue":"2","key":"10.1016\/j.intimp.2026.116981_bb0225","doi-asserted-by":"crossref","first-page":"L222","DOI":"10.1152\/ajplung.00327.2005","article-title":"NKG2D ligands are expressed on stressed human airway epithelial cells","volume":"291","author":"Borchers","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.intimp.2026.116981_bb0230","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2019-129998","article-title":"Next generation NKG2D-based CAR T-cells (CYAD-02): co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo","volume":"134","author":"Fontaine","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116981_bb0235","doi-asserted-by":"crossref","unstructured":"Fuertes, M.B., C.I. Domaica, and N.W. Zwirner, Leveraging NKG2D ligands in Immuno-oncology. Front. Immunol., 2021. Volume 12\u20132021.","DOI":"10.3389\/fimmu.2021.713158"},{"issue":"6","key":"10.1016\/j.intimp.2026.116981_bb0240","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jhep.2021.01.017","article-title":"Expression of NKG2D ligands is downregulated by \u03b2-catenin signalling and associates with HCC aggressiveness","volume":"74","author":"Cadoux","year":"2021","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116981_bb0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/07357900701208824","article-title":"Comparison of level of NKG2D ligands between Normal and tumor tissue using multiplex RT-PCR","volume":"25","author":"Park","year":"2007","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.intimp.2026.116981_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab018","article-title":"A Summary of Current NKG2D-Based CAR Clinical Trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"10.1016\/j.intimp.2026.116981_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omto.2022.04.003","article-title":"Chimeric anti-GPC3 sFv-CD3\u03b5 receptor-modified T cells with IL7 co-expression for the treatment of solid tumors","volume":"25","author":"Sun","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"7775","key":"10.1016\/j.intimp.2026.116981_bb0260","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","article-title":"Structural basis of assembly of the human T cell receptor\u2013CD3 complex","volume":"573","author":"Dong","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2026.116981_bb0265","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human Gamma Delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.116981_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060998","article-title":"CAR-\u03b3\u03b4 T cells targeting Claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells","volume":"17","author":"Zhao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.116981_bb0275","doi-asserted-by":"crossref","unstructured":"X.B. Perez, et al., CAR Signaling informs mechanisms to EnhanceMetabolism and function in \u03b3\u03b4 T cells, Res Sq[Preprint]. rs.3.rs-8704178 (2026).","DOI":"10.21203\/rs.3.rs-8704178\/v1"},{"issue":"12","key":"10.1016\/j.intimp.2026.116981_bb0280","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1080\/14712598.2020.1803273","article-title":"Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D\/NKG2D-ligand system","volume":"20","author":"Lazarova","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.116981_bb0285","doi-asserted-by":"crossref","first-page":"837","DOI":"10.37349\/ei.2024.00176","article-title":"Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer","volume":"4","author":"Mirgayazova","year":"2024","journal-title":"Exploration of Immunology"},{"key":"10.1016\/j.intimp.2026.116981_bb0290","doi-asserted-by":"crossref","first-page":"217771","DOI":"10.1016\/j.canlet.2025.217771","article-title":"The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency","volume":"626","author":"Bao","year":"2025","journal-title":"Cancer Lett."},{"issue":"8047","key":"10.1016\/j.intimp.2026.116981_bb0295","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.intimp.2026.116981_bb0300","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1016\/j.molcel.2021.07.035","article-title":"Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells","volume":"81","author":"Donohoue","year":"2021","journal-title":"Mol. Cell"},{"issue":"25","key":"10.1016\/j.intimp.2026.116981_bb0305","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of \u03b6-deficient CARs into the CD3\u03b6 gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:11Z","timestamp":1785887051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926008271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"alternative-id":["S1567576926008271"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116981","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of super V\u03b42 T cells for relapsed\/refractory acute myeloid Leukemia via non-viral site-specific integration","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116981"}}